Genmab Outlines Development Plans For HuMax-CD4 After Regaining Rights From Merck Serono
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck returns rights to the investigational T-cell lymphoma candidate for strategic reasons prior to seeing Phase III data.